Denileukin diftitox
Clinical data | |
---|---|
Trade names | Ontak |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611024 |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 70-80 min |
Identifiers | |
| |
CAS Number | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider |
|
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C2560H4042N678O799S17 |
Molar mass | 57647.46 g·mol−1 |
(what is this?) (verify) |
Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining
interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas
, malignant cells express these receptors, so denileukin diftitox can target these.
In 1999, Ontak was approved by the
U.S. Food and Drug Administration (FDA) for treatment of Cutaneous T-cell lymphoma (CTCL).[2]
There is some evidence tying it to vision loss, and in 2006 the FDA added a
black box warning to the drug's label.[3]
In 2014, marketing of Ontak was discontinued in the US.[4]
References
- S2CID 9028829.
- S2CID 23956460.
- PMID 21188096.
- ^ "FDA Drug Shortages". U.S. Food and Drug Administration. 31 January 2014. Retrieved 3 July 2017.